Related Experiment Video
Updated: Jun 10, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
A Recurring Theme: A Rare Case of Pembrolizumab-induced Acute Interstitial Nephritis
Jonathan London1, Sabrina Bulancea1, Inaas Shirazi1
1Department of Internal Medicine, Long Island Community Hospital, USA.
Abstract:
Pembrolizumab is utilized in the treatment of multiple different malignancies, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, renal cell carcinoma, endometrial cancer, and more. Pembrolizumab is an immune checkpoint inhibitor that inhibits the programmed cell death-1 (PD-1) signaling pathway. Despite its benefits in treating multiple cancers, there are many reported adverse effects of Pembrolizumab affecting various organ systems; rarely it can cause acute interstitial nephritis (AIN). We present the case of a 79-year-old male with metastatic retroperitoneal squamous cell carcinoma who was found to have recurrent acute interstitial nephritis after pembrolizumab therapy.
More Related Videos
Related Concept Videos
Acute Pyelonephritis I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Nephrotic Syndrome I : Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Pyelonephritis II: Diagnostic Studies and Management

